Clinical Trial Update: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of lutikizumab in adults and adolescents with moderate to severe hidradenitis suppurativa (HS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Lutikizumab (lutikizumab)

Snippet

Sponsor: AbbVie | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: ACTIVE_NOT_RECRUITING